News
NOTV
2.017
+1.86%
0.037
Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024
Inotiv will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on August 8, 2024. The Company will host a conference call that same day to discuss the results. Inotiv is a leading contract research organization specializing in drug discovery and development.
Barchart · 1d ago
Weekly Report: what happened at NOTV last week (0715-0719)?
Weekly Report · 4d ago
Inotiv (NOTV) Gets a Buy from Craig-Hallum
TipRanks · 07/19 13:25
Weekly Report: what happened at NOTV last week (0708-0712)?
Weekly Report · 07/15 10:45
Weekly Report: what happened at NOTV last week (0701-0705)?
Weekly Report · 07/08 10:47
Weekly Report: what happened at NOTV last week (0624-0628)?
Weekly Report · 07/01 10:47
Weekly Report: what happened at NOTV last week (0617-0621)?
Weekly Report · 06/24 10:53
Weekly Report: what happened at NOTV last week (0610-0614)?
Weekly Report · 06/17 10:46
Analysts Offer Insights on Healthcare Companies: Semler Scientific (SMLR) and Inotiv (NOTV)
TipRanks · 06/10 13:00
Inotiv (NOTV) Receives a Buy from Craig-Hallum
TipRanks · 06/10 12:45
Inotiv Completes Hillcrest, UK Expansion, Secures Long-Term Contracts with New Customers
Hillcrest, U.K. Expansion project completed Extension of the maturity date of the $3.7 million OBRC payable note to July 2025. Inotiv is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services.
Benzinga · 06/10 11:37
INOTIV, INC. PROVIDES BUSINESS UPDATES
Reuters · 06/10 11:30
INOTIV INC: EXTENSION OF MATURITY DATE OF $3.7 MLN OBRC PAYABLE NOTE TO JULY 2025
Reuters · 06/10 11:30
Weekly Report: what happened at NOTV last week (0603-0607)?
Weekly Report · 06/10 10:48
Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Dexcom (DXCM) and CareDx (CDNA)
TipRanks · 06/04 13:20
Analysts Conflicted on These Healthcare Names: Inotiv (NOTV), BioNTech SE (BNTX) and Augmedix (AUGX)
TipRanks · 06/04 13:01
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers FibroGen stock moved upwards by 24.4% to $1.53 during Monday's after-market session. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12%. Scholar Rock Holding shares rose 6.96% in the after- market. Losers Bright Green and Concord Medical Services stock fell 7.4%.
Benzinga · 06/03 20:31
UPDATE 1-US breeder Envigo pleads guilty for mistreating beagles, gets $22 million fine
US breeder Envigo pleads guilty for mistreating beagles, gets $22 million fine for animal welfare violations. Indiana-based company agreed to pay $11 million in the largest-ever fine in an animal welfare case. Some 4,000 beagles were euthanized and some adopted by celebrities.
Reuters · 06/03 18:31
Inotiv to Pay $35M for Canine-Breeding Facility Violations
Dow Jones · 06/03 18:00
INOTIV REACHES AGREEMENT TO RESOLVE PREVIOUSLY-ANNOUNCED INVESTIGATION INTO SHUTTERED CUMBERLAND FACILITY
Reuters · 06/03 17:24
More
Webull provides a variety of real-time NOTV stock news. You can receive the latest news about Inotiv Inc through multiple platforms. This information may help you make smarter investment decisions.
About NOTV
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.